REGENXBIO Full Year 2022 Earnings: Revenues Disappoint
REGENXBIO (NASDAQ:RGNX) Full Year 2022 Results
Key Financial Results
Revenue: US$112.7m (down 76% from FY 2021).
Net loss: US$280.3m (down by 319% from US$127.8m profit in FY 2021).
US$6.50 loss per share (down from US$3.01 profit in FY 2021).
All figures shown in the chart above are for the trailing 12 month (TTM) period
REGENXBIO Revenues Disappoint
Revenue missed analyst estimates by 6.4%. Earnings per share (EPS) was mostly in line with analyst estimates.
Looking ahead, revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in the US.
Performance of the American Biotechs industry.
The company's shares are up 11% from a week ago.
Risk Analysis
We don't want to rain on the parade too much, but we did also find 1 warning sign for REGENXBIO that you need to be mindful of.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here